Biomerica (NASDAQ:BMRA) Share Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Biomerica, Inc. (NASDAQ:BMRA) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.85 and traded as low as $2.44. Biomerica shares last traded at $2.47, with a volume of 10,956 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biomerica in a report on Tuesday, October 14th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Biomerica Stock Down 3.5%

The stock has a market capitalization of $7.46 million, a PE ratio of -2.57 and a beta of 0.11. The stock’s 50-day moving average is $2.48 and its 200 day moving average is $2.85.

Biomerica (NASDAQ:BMRA) last released its earnings results on Wednesday, January 14th. The company reported ($0.45) earnings per share (EPS) for the quarter. Biomerica had a negative return on equity of 83.73% and a negative net margin of 90.29%.The company had revenue of $1.21 million during the quarter.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.